Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Family Office Seeking 510K Devices Throughout US

23 Mar

A Venture Fund/Family Office founded in 2002 and based in Nashville Tennessee is looking to make series A rounds of approximately $1.0 – $1.5 million in rounds totaling $3-$7 million. The firm is open to investing into companies located throughout the United States and makes approximately 2-4 new investments per year.

Within life sciences, the firm is most interested in companies in the medical device and diagnostics space. The firm is looking for companies that have a 510k regulatory pathway with at least a working prototype of the product and preferably some in-human data. The firm is generally open to all indications with particular interest in oncology, rare cancers, diabetes, neurology, ophthalmology and cardiology. The firm is especially interested in CLIA lab diagnostics, software enabled devices, molecular diagnostics for rare cancers and diseases, and algorithms that interpret genetic information and recommend treatment options. The firm is also interested in nutraceuticals, expedited drug development, HIT and business to business technology companies although these areas are less of a focus.

The firm is looking for private companies with experienced management team and looks to take a board seat following investment. The firm looks to be a hands on investor and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Global VC with New Fund Seeking Innovative Therapeutics

23 Mar

Venture Capital firm with offices in the US, Canada and Europe focuses on seed and series A and B investments in early stage biotechnology companies, as well as growth equity investments in medical devices companies. The firm’s typical investment size for early stage companies is $5M-$15M and the firm can allocate up to $35-40M total over the life of an investment. The firm focuses on companies that are based in the U.S., Canada and Europe and is actively seeking new investment opportunities.

In early 2017, the firm closed its newest fund that will use a diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics. The fund will invest in approximately 20‐25 biotechnology companies in the U.S., Canada and Europe.

The firm is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address oncology, orphan or genetic based diseases, inflammation, infectious diseases, fibrosis and CNS indications. The firm also is interested in regenerative medicine. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. The firm prefers devices with proof-of-concept and strong IP.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Family Office Seeking Seed Stage Investment Opportunities in Healthcare

23 Mar

Family office based in Seattle, WA typically provides $50K equity capital to seed stage companies in the life science space, but has invested up to $500K in the past. The firm is looking to make about 2-3 investments per year. Additionally, the firm will provide strategic and directional expertise to their portfolio companies and support their growth to later developmental stages. The firm considers US-based companies with a focus in the West Coast.

The firm is open to all sectors within the life science space including therapeutics, diagnostics, medical technology, and healthcare IT. The firm is particularly interested in companies developing therapeutic products of all indications, as the firm’s strongest expertise lies in this space. The firm will consider companies with assets that are pre-clinical or in Phase I clinical trials. In terms of medical technology, the firm will consider medical devices in development or undergoing clinical trials, and is open to those in 510k and PMA regulatory pathways.

The firm is a passive, early-stage investor and will not require a board seat in portfolio companies. The firm seeks to work with passionate, experienced entrepreneurs with a track record of success, but will not rule out companies that are run by first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Chinese PE Firm Seeking US Based Clinical Stage Therapeutics, Devices and Diagnostics

23 Mar

PE firm founded in 2015 and is based in Beijing, China has approximately $100M assets under management and manages 2 active funds – the RMB and USD Funds – that focus on investments in the life science space. The RMB Fund invests $5-40 M in companies based in China, and the USD Fund invests $5-10 M in companies of all parts of the world, with a focus in US and China. With these funds, the firm will make 1-2 investments per year in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and healthcare IT. The firm will not consider companies with pre-clinical or early clinical assets. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 1: Cross-Border Fund Invests in Highly Innovative Early Stage Medtech, Diagnostics and Healthcare IT

16 Mar

A VC firm with offices in California, Beijing, and Hong Kong manages over 100 portfolio companies in the US and China. The firm generally invests in the early stages, mostly in seed and Series A rounds. The firm focuses its investments in U.S. and China, but also considers companies based in Canada.

In the life sciences sector, the firm will consider medical technology, diagnostic, and healthcare IT companies. The firm is open to all types of medical technology in all types of indications, and will look at both 510k and PMA medical devices in development or clinical trials. Previously, the firm has also invested in the synthetic engineering space.

The firm is looking for early-stage companies with a highly innovative product. The management team of potential portfolio companies is expected to be committed to the company full-time and will have a track of strong, successful entrepreneurship. The firm does not require a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Seed Investment Firm Raises New Fund, Seeks Healthcare IT Opportunities

16 Mar

An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: China-based Firm Invests in Preclinical Drugs in Oncology and Chronic Diseases

16 Mar

The biotech and healthcare subsidiary company of a large real estate corporation in China is interested in biotech technology, products and services with large potential in the Chinese market. The firm aims to launch them in China through partnership, investment and cooperation. Typical equity investments range from US$0.7-1.5 million (RMB 5-10 million), up to 3.5 million in later stage companies. The firm prefers to co-invest in a round with a strong, reputable lead. The firm considers opportunities from around the world with a focus on China, the US, and Australia.

The firm is interested in preclinical therapeutic projects in oncology, chronic diseases such as diabetes, and other disease indications with large market potential. The firm is open to all therapeutic modalities.

The firm is looking for experienced teams backed by strong lead investors. The firm may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com